Pillar Biosciences Inc. of Natick announced Thursday a partnership with North Carolina-based Labcorp to provide genomic testing for people with cancer.
ORI Capital exits Kymab in $1.1b deal with Sanofi, hits first close of $400m second fund Premium
ORI Capital, a Hong Kong-based healthcare sector-focused investment firm, announced that it has exited biopharmaceutical firm Kymab, the largest investment in its first healthcare fund, in a $1.1 billion deal with Sanofi.
Continue reading this story with a subscription to DealStreetAsia.
Contact us for corporate subscriptions at subs@dealstreetasia.com.
Sign up for our newsletter - The Daily Brief Opt out of receiving The Daily Brief in your inbox everyday
REGISTER stories left placeholder You have one free story left this month. You have stories left placeholder free stories left this month.